Newron Pharmaceuticals S.p.A. (NWRN.SW)

CHF 6.46

(0.62%)

Long Term Debt Summary of Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.'s latest annual long term debt in 2023 was 25.96 Million EUR , down -42.52% from previous year.
Newron Pharmaceuticals S.p.A.'s latest quarterly long term debt in 2024 Q2 was 48.53 Million EUR , down 0.0% from previous quarter.
Newron Pharmaceuticals S.p.A. reported annual long term debt of 45.16 Million EUR in 2022, up 6.17% from previous year.
Newron Pharmaceuticals S.p.A. reported annual long term debt of 42.54 Million EUR in 2021, up 65.7% from previous year.
Newron Pharmaceuticals S.p.A. reported quarterly long term debt of 34.21 Million EUR for 2023 Q2, down 0.0% from previous quarter.
Newron Pharmaceuticals S.p.A. reported quarterly long term debt of 25.96 Million EUR for 2023 FY, down -42.52% from previous quarter.

Annual Long Term Debt Chart of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Historical Annual Long Term Debt of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Year	Long Term Debt	Long Term Debt Growth
2023	25.96 Million EUR	-42.52%
2022	45.16 Million EUR	6.17%
2021	42.54 Million EUR	65.7%
2020	25.67 Million EUR	53.29%
2019	16.74 Million EUR	13299.2%
2018	125 Thousand EUR	0.0%
2017	- EUR	0.0%
2016	- EUR	-100.0%
2015	364 Thousand EUR	-50.07%
2014	729 Thousand EUR	-32.93%
2013	1.08 Million EUR	-24.88%
2012	1.44 Million EUR	-19.7%
2011	1.8 Million EUR	0.0%
2010	- EUR	100.0%
2009	-2.65 Million EUR	-1039.22%
2008	283 Thousand EUR	-49.55%
2007	561 Thousand EUR	-32.65%
2006	833 Thousand EUR	-19.67%
2005	1.03 Million EUR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	48.53 Million EUR	0.0%
2023 Q2	34.21 Million EUR	0.0%
2023 FY	25.96 Million EUR	-42.52%
2023 Q4	25.96 Million EUR	0.0%
2022 Q2	43.88 Million EUR	0.0%
2022 FY	45.16 Million EUR	6.17%
2022 Q4	45.16 Million EUR	0.0%
2021 FY	42.54 Million EUR	65.7%
2021 Q4	42.54 Million EUR	0.0%
2021 Q2	26.37 Million EUR	0.0%
2020 Q4	25.67 Million EUR	0.0%
2020 FY	25.67 Million EUR	53.29%
2020 Q2	24.7 Million EUR	0.0%
2019 Q2	9.34 Million EUR	0.0%
2019 Q4	16.74 Million EUR	0.0%
2019 FY	16.74 Million EUR	13299.2%
2018 Q4	125 Thousand EUR	0.0%
2018 FY	125 Thousand EUR	0.0%
2018 Q2	- EUR	0.0%
2017 Q2	- EUR	0.0%
2017 FY	- EUR	0.0%
2017 Q4	- EUR	0.0%
2016 Q2	182 Thousand EUR	0.0%
2016 Q4	- EUR	0.0%
2016 FY	- EUR	-100.0%
2015 Q4	364 Thousand EUR	0.0%
2015 FY	364 Thousand EUR	-50.07%
2015 Q2	549 Thousand EUR	0.0%
2014 Q2	907 Thousand EUR	0.0%
2014 FY	729 Thousand EUR	-32.93%
2014 Q4	729 Thousand EUR	0.0%
2013 Q4	1.08 Million EUR	0.0%
2013 Q2	1.26 Million EUR	0.0%
2013 FY	1.08 Million EUR	-24.88%
2012 Q2	1.62 Million EUR	0.0%
2012 Q4	1.44 Million EUR	0.0%
2012 FY	1.44 Million EUR	-19.7%
2011 Q2	1.98 Million EUR	0.0%
2011 FY	1.8 Million EUR	0.0%
2011 Q4	1.8 Million EUR	0.0%
2010 Q2	-2.77 Million EUR	0.0%
2010 FY	- EUR	100.0%
2010 Q4	- EUR	0.0%
2009 Q4	-2.65 Million EUR	0.0%
2009 FY	-2.65 Million EUR	-1039.22%
2008 FY	283 Thousand EUR	-49.55%
2007 FY	561 Thousand EUR	-32.65%
2006 FY	833 Thousand EUR	-19.67%
2005 FY	1.03 Million EUR	0.0%

Peer Long Term Debt Comparison of Newron Pharmaceuticals S.p.A.

Name	Long Term Debt	Long Term Debt Difference
Addex Therapeutics Ltd	70.38 Thousand CHF	-36789.741%
BB Biotech AG	304.9 Million CHF	91.485%
Basilea Pharmaceutica AG	95.45 Million CHF	72.801%
Evolva Holding SA	- CHF	-Infinity%
Idorsia Ltd	931 Million CHF	97.211%
Kuros Biosciences AG	1.56 Million CHF	-1558.978%
Molecular Partners AG	2.44 Million CHF	-962.316%
Relief Therapeutics Holding AG	9000.00 CHF	-288377.778%
Santhera Pharmaceuticals Holding AG	1.47 Million CHF	-1656.631%